Possis Medical Shareholder Suit Dismissed on Appeal

  
    
  
  
    
      Possis Medical, Inc. (NASDAQ: POSS), a developer, manufacturer and 
      marketer of pioneering medical devices used in endovascular procedures, 
      today announced that the United States Court of Appeals for the Eighth 
      Circuit has affirmed the Federal District Court's dismissal of a 
      shareholder lawsuit that was filed June 5, 2005. The suit had alleged 
      that Possis Medical violated federal securities laws by misrepresenting 
      material information about the Company’s 
      AngioJet® Rheolytic™ 
      Thrombectomy System prior to the August 2004 public disclosure of the 
      results of the Company’s AiMI clinical trial. 
      The United States District Court for the District of Minnesota had 
      previously dismissed with prejudice the consolidated amended complaint 
      in a shareholder class action lawsuit filed against Possis Medical and 
      two of its executive officers, entitled “In re 
      Possis Medical, Inc., Securities Litigation.”
    
    
      “We are very pleased that the appellate court 
      has dismissed this case. Although we have always been firm in our 
      conviction that this suit was without merit, it confirms our confidence 
      in the judicial process to have the court take this action,” 
      commented Robert G. Dutcher, chairman, president and chief executive 
      officer of Possis Medical Inc.
    
    
      About Possis Medical, Inc.
    
    
      Possis Medical, Inc., develops, manufactures and markets pioneering 
      medical devices for the large and growing cardiovascular and vascular 
      treatment markets. The Company’s AngioJet® 
      System is the world’s leading mechanical 
      thrombectomy system with FDA approval to remove large and small thrombus 
      from coronary arteries, coronary bypass grafts, peripheral arteries and 
      veins, A-V grafts and native fistulas.